Aethlon Medical Inc. has presented an overview of its Hemopurifier® technology, highlighting its unique mechanism of action in blood purification. The device has demonstrated potential in early clinical trials to clear enveloped viruses and extracellular vesicles (EVs) both in vitro and in patients. Aethlon has received two FDA "Breakthrough Device" designations for its applications in advanced/metastatic cancer and the treatment of life-threatening viruses without approved therapies. The company is actively enrolling patients in an oncology trial in Australia and is engaged in ongoing research and development for Long COVID. The Hemopurifier® has been administered in 164 sessions across 38 patients, showing a favorable safety profile. Aethlon's broad patent portfolio supports its competitive advantage, with opportunities for future expansion in various therapeutic areas. You can access the full presentation through the link below.